← Eichor
Condition: Endometrial Cancer Recurrent Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Endometrial Cancer Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06413992Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unr
Phase 1 · 1 location(s) · Aaron Wolfson · NCT05603910Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Phase 2 · 2 location(s) · Panagiotis Konstantinopoulos, MD, PhD · NCT06518564ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666Endometrial Cancer Lymphadenectomy Trial
NA · 61 location(s) · Philipps University Marburg · NCT03438474Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer
NA · 1 location(s) · Denise Fabian · NCT07631572BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1 · 4 location(s) · Bio-Path Holdings, Inc. · NCT04196257Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT03968406Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Phase 2/Phase 3 · 83 location(s) · Kartos Therapeutics, Inc. · NCT05797831Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT04403867PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Phase N/A · 1 location(s) · Radboud University Medical Center · NCT03621904Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2 · 1 location(s) · Shandong University · NCT04716686HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2 · 28 location(s) · Hansoh BioMedical R&D Company · NCT06014190An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV
NA · 1 location(s) · Roswell Park Cancer Institute · NCT06855706A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Phase 1/Phase 2 · 21 location(s) · Alliance Foundation Trials, LLC. · NCT04486352A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07209449Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
Phase 2 · 1 location(s) · Alessandro Santin · NCT03832361Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · 242 location(s) · National Cancer Institute (NCI) · NCT07198074CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05410717A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Phase 2 · 1 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT06522828Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377[18F]FES PET/.CT in Uterine Cancer
Phase 2 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT05916196A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Ute
Phase 3 · 171 location(s) · BioNTech SE · NCT06340568A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemi
Phase 1/Phase 2 · 24 location(s) · Regeneron Pharmaceuticals · NCT04590326IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre
Phase 3 · 250 location(s) · AstraZeneca · NCT06989112A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
Phase N/A · 2 location(s) · Sun Yat-sen University · NCT06781151Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ova
Phase 1/Phase 2 · 52 location(s) · Regeneron Pharmaceuticals · NCT03564340
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.